Company Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
| Country | United States |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Sing Wong |
Contact Details
Address: 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922 United States | |
| Phone | 908 517 7330 |
| Website | cyclacel.com |
Stock Details
| Ticker Symbol | CYCC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130166 |
| CUSIP Number | 23254L603 |
| ISIN Number | US23254L8019 |
| Employer ID | 91-1766850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sing Ee Wong | Chief Executive Officer and Executive Director |
| Spiro George Rombotis | President |
| Dr. Brian Schwartz M.D. | Chief Medical Officer |
| Cu Seng Kiu | Chief Financial Officer |
| Gill Christie | Director of Human Resources |
| Grace Kim | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 25, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 24, 2025 | PRE 14C | Filing |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 5, 2025 | SC 14F1 | Filing |
| Mar 4, 2025 | SCHEDULE 13D | Filing |
| Feb 28, 2025 | SCHEDULE 13D | Filing |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |